Primary Lateral Sclerosis (PLS)

Migration, Crosslink

📖

Primary Lateral Sclerosis (PLS)

active

wiki page Created: 2026-04-02T07:20:11 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-diseases-primary-lateral-sclerosis

📖 Wiki Page

disease2153 wordssynced 2026-04-02

Primary Lateral Sclerosis

Overview

Primary Lateral Sclerosis is a condition with relevance to the neurodegenerative disease landscape. This page covers its molecular basis, clinical features, genetic associations, and connections to broader neurodegeneration research.

Primary Lateral Sclerosis (PLS) is a rare, progressive neurodegenerative disorder characterized by selective degeneration of the upper motor neurons (corticospinal tract) in the motor cortex. Unlike Amyotrophic Lateral Sclerosis (ALS) - /diseases/amyotrophic-lateral-sclerosis, PLS spares lower motor neurons, resulting in a distinct clinical phenotype with predominant spasticity and rigidity without muscle wasting or fasciculations[@pringle1992].

Epidemiology

Primary Lateral Sclerosis is a rare condition, accounting for approximately 2-3% of all motor neuron diseases[@tartaglia2007]. The estimated annual incidence is 0.1-0.2 per 100,000 population[@iwata2011]. PLS typically presents in middle to late adulthood, with a mean age of onset between 45-55 years[@singer2007]. There appears to be a slight male predominance, though this varies across studies[@zhai2021]. Approximately 10-15% of patients initially diagnosed with PLS will eventually develop lower motor neuron involvement and be reclassified as having ALS[@chio2021].

Pathophysiology

Upper Motor Neuron Degeneration

PLS is characterized by selective degeneration of the corticospinal motor neurons located in the motor cortex (Brodmann areas 4 and 6)[@konno1986]. The pathophysiological hallmarks include:

...

Primary Lateral Sclerosis

Overview

Primary Lateral Sclerosis is a condition with relevance to the neurodegenerative disease landscape. This page covers its molecular basis, clinical features, genetic associations, and connections to broader neurodegeneration research.

Primary Lateral Sclerosis (PLS) is a rare, progressive neurodegenerative disorder characterized by selective degeneration of the upper motor neurons (corticospinal tract) in the motor cortex. Unlike Amyotrophic Lateral Sclerosis (ALS) - /diseases/amyotrophic-lateral-sclerosis, PLS spares lower motor neurons, resulting in a distinct clinical phenotype with predominant spasticity and rigidity without muscle wasting or fasciculations[@pringle1992].

Epidemiology

Primary Lateral Sclerosis is a rare condition, accounting for approximately 2-3% of all motor neuron diseases[@tartaglia2007]. The estimated annual incidence is 0.1-0.2 per 100,000 population[@iwata2011]. PLS typically presents in middle to late adulthood, with a mean age of onset between 45-55 years[@singer2007]. There appears to be a slight male predominance, though this varies across studies[@zhai2021]. Approximately 10-15% of patients initially diagnosed with PLS will eventually develop lower motor neuron involvement and be reclassified as having ALS[@chio2021].

Pathophysiology

Upper Motor Neuron Degeneration

PLS is characterized by selective degeneration of the corticospinal motor neurons located in the motor cortex (Brodmann areas 4 and 6)[@konno1986]. The pathophysiological hallmarks include:

Axonal degeneration of corticospinal tract fibers
Loss of Betz cells in layer V of the motor cortex
Myelin pallor and gliosis in the descending motor pathways
Spongiform changes in the precentral gyrus

Molecular Mechanisms

The molecular pathogenesis of PLS involves several interconnected mechanisms:

Excitotoxicity: Excessive glutamate signaling leads to calcium-mediated neuronal damage through overactivation of NMDA and AMPA receptors[@rothstein1995].

Oxidative Stress: Increased reactive oxygen species (ROS) accumulation damages cellular proteins, lipids, and DNA in motor neurons[@beal2002].

Mitochondrial Dysfunction: Impaired mitochondrial energy metabolism contributes to neuronal vulnerability and ATP depletion triggering apoptosis[@mattiazzi2002].

Cytoskeletal Abnormalities: Disruption of axonal transport machinery, including tubulin acetylation defects and dynein/dynactin dysfunction, impairs trafficking of essential cellular components[@de2009].

Neuroinflammation: Activated microglia and astrocytes release pro-inflammatory cytokines that exacerbate neuronal injury[@mcgeer2002].

Genetic Factors

While most cases of PLS are sporadic, approximately 5-10% are familial[@valdmanis2007]. Known genetic associations include:

ALSgenes (SUPERG, ALS2): Some patients carry mutations in genes also associated with familial ALS[@siddique2009]
SPG3A gene (atlastin-1): Linked to hereditary spastic paraplegia but can present with PLS phenotypes[@durr2000]
HTRA1 mutations: Associated with PLS and neurodegeneration[@sepulvedafalla2014]

Clinical Presentation

Core Symptoms

The clinical presentation of PLS evolves gradually over years, typically beginning in the legs and progressing upward[@gotkine2007]:

Spasticity: The hallmark feature, presenting as velocity-dependent increase in muscle tone with hyperreflexia[@young1994]

Initially affects lower extremities
Causes gait disturbance, scissoring, and falls
Progresses to involve trunk and upper limbs

Pseudobulbar Affect: Emotional lability with involuntary crying or laughing episodes[@schiffer2006]

Bradykinesia: Slowness of voluntary movement due to corticospinal involvement[@quinn2020]

Fatigue: Early and prominent exercise intolerance[@lou2009]

Disease Progression

The progression of PLS follows a characteristic pattern[@bruijn2004]:

| Stage | Features | Time Course |
|-------|----------|-------------|
| Early | Leg spasticity, gait difficulty | 0-3 years |
| Middle | Upper limb involvement, dysarthria | 3-7 years |
| Advanced | Severe disability, dysphagia, respiratory compromise | 7-15 years |

Distinction from ALS

Key differentiating features include[@pringle1999]:

Absence of muscle atrophy: PLS patients maintain muscle bulk
No fasciculations: Lower motor neuron signs are absent
Slower progression: Disease course extends over decades
Preserved sensory examination: Sensory function remains intact

Diagnosis

Clinical Criteria

The diagnostic criteria for PLS require[@stark2021]:

Age >25 years at symptom onset

Gradual progression of spastic paraparesis for at least 3 years

Absence of family history (for sporadic cases)

Normal EMG showing no lower motor neuron involvement

Exclusion of other conditions mimicking PLS

Diagnostic Workup

| Test | Purpose |
|------|---------|
| MRI brain and spine | Rule out structural lesions, show corticospinal tract hyperintensity |
| EMG/NCS | Exclude lower motor neuron involvement, confirm preserved sensory responses |
| CSF analysis | Exclude inflammatory/infectious processes |
| Genetic testing | Consider in familial cases or early onset |
| PET imaging | May show hypometabolism in motor cortex |

Differential Diagnosis

Conditions to exclude include[@younger1998]:

Amyotrophic Lateral Sclerosis - /diseases/amyotrophic-lateral-sclerosis
Hereditary spastic paraplegia
Multiple sclerosis
Adulthood leukodystrophies
Structural spinal cord lesions
Vitamin B12 deficiency
Copper deficiency myelopathy

Treatment and Management

Pharmacological Approaches

Symptomatic Management

Spasticity Treatment[@francisco2021]:

Baclofen: GABA-B agonist, starting 5-10mg TID, titrating to 30-60mg/day
Tizanidine: Alpha-2 adrenergic agonist, 2-8mg TID
Benzodiazepines: Diazepam or clonazepam for severe spasticity
Dantrolene sodium: Direct calcium antagonist, reserved for severe cases due to hepatotoxicity

Pseudobulbar Affect[@schiffer2006a]:

Dextromethorphan/quinidine: FDA-approved for PBA, 20/10mg BID
Valbenazine: VMAT2 inhibitor, 40-80mg daily
Tetrabenazine: Alternative VMAT2 inhibitor

Muscle Cramps and Pain:

Quinine sulfate: 200-300mg TID (monitor for cardiac effects)
Mexiletine: Sodium channel blocker, 150-300mg TID

Disease-Modifying Therapies

While no therapies are FDA-approved specifically for PLS, emerging approaches target underlying pathophysiological mechanisms[@jaiswal2019]:

Riluzole: Glutamate antagonist, modestly slows progression in ALS (potential benefit in PLS)

Edaravone: Antioxidant, FDA-approved for ALS

AMX0035 (Relyvrio):Targets mitochondrial dysfunction and oxidative stress

Gene therapy approaches: Under investigation for specific genetic forms

Non-Pharmacological Interventions

Rehabilitation

Physical therapy: Stretching, strengthening, gait training
Occupational therapy: Adaptive devices, energy conservation
Speech therapy: For dysarthria and dysphagia management

Assistive Devices

Walking aids: Canes, walkers, wheelchairs as disease progresses
Orthotics: Ankle-foot orthoses for foot drop
Communication devices: For advanced disease with severe dysarthria

Nutritional Support

Dietary counseling: Maintain adequate caloric intake
Feeding tube placement: Consider PEG tube for dysphagia
Weight monitoring: Prevent malnutrition

Emerging Therapies

Clinical Trials

Several therapeutic approaches are under investigation[@benatar2022]:

Antisense oligonucleotides (ASOs): Targeting specific genetic mutations
Stem cell therapy: Neural progenitor cell transplantation
Immunotherapy: Anti-inflammatory and neuroprotective approaches
Repurposed drugs: Clinical trials for existing medications

Research Directions

Key areas of active investigation include[@turner2009]:

Biomarker development for early diagnosis and progression tracking
Understanding genotype-phenotype correlations
Developing sensitive outcome measures for clinical trials
Exploring neuroprotective strategies

Brain-Computer Interface Therapy

Brain-computer interfaces (BCIs) offer significant potential for patients with Primary Lateral Sclerosis, primarily for communication support and motor rehabilitation[@wolpaw2004].

Current Applications

Motor imagery BCI: Enables control of external devices through imagined movements
Communication aids: BCI-based AAC systems for patients with speech impairment
Movement monitoring: Tracks upper motor neuron activity and disease progression
Rehabilitation training: Combined BCI with physical therapy for spasticity management

Emerging Technologies

AI-enhanced decoding: Improved accuracy for neural signal interpretation
Wearable BCI systems: Non-invasive options for home use
Brain-machine integration: Direct neural control of assistive devices

Clinical Evidence

Research on PLS-specific BCI applications is limited, but studies on related motor neuron conditions demonstrate the potential. Motor imagery BCIs have shown efficacy in upper motor neuron disorders, with rehabilitation applications showing promise for spasticity management[@pichiorri2015].

Cross-References

Motor Imagery Brain-Computer Interface
Brain-Computer Interface Technologies
BCI-Assisted Rehabilitation

[@wolpaw2004]: Wolpaw JR, et al. Brain-computer interfaces for communication and control. Proceedings of the IEEE. 2004;92(7):1082-1093. Available from: https://doi.org/10.1109/JPROC.2004.829006

[@pichiorri2015]: Pichiorri F, et al. Brain-computer interface aids for the rehabilitation of stroke patients. Brain Stimulation. 2015;8(3):482-490. Available from: https://doi.org/10.1016/j.brs.2014.12.001

Prognosis

The prognosis for PLS is generally more favorable than ALS[@wicks2007]:

Life expectancy: Near-normal or only modestly reduced
Progression rate: Very slow, typically decades to severe disability
Cause of death: Respiratory complications in advanced disease
Quality of life: Significantly impacted by spasticity and disability

Research Directions

Current Knowledge Gaps

Biomarkers: Need for sensitive diagnostic and progression biomarkers

Genetics: Better understanding of hereditary forms

Disease modification: Lack of effective disease-modifying therapies

Clinical trials: Need for validated outcome measures

Active Research Areas

Neuroimaging biomarkers (DTI, PET)
Neurophysiological markers
Genetic predisposition factors
Therapeutic target validation

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

Recent Research (2024-2026)

[Shah JS, Oskarsson B, Zhou X et al., Expanding the Motor Band Sign in Motor Neuron Disease Using 7T MRI (2026)](https://pubmed.ncbi.nlm.nih.gov/41792976/) - Muscle Nerve

[Sorenson E, Heitzman D, Lee I et al., Prospective Validation of the New PLS Diagnostic Criteria (2026)](https://pubmed.ncbi.nlm.nih.gov/41772409/) - Muscle Nerve

[Scirocco E, Scalia J, Ugolini B et al., The Amyotrophic Lateral Sclerosis House Call Program: A Single-Center Experience (2026)](https://pubmed.ncbi.nlm.nih.gov/41769387/) - Neurol Res Int

[Sia T, Sheehy TP, Morgan P et al., Trajectory of Mobility Function Decline for People With Motor Neuron Disease (2026)](https://pubmed.ncbi.nlm.nih.gov/41654003/) - Arch Phys Med Rehabil

[Matsubara T, Kihara N, Miyatake S et al., TBK1-Associated Primary Lateral Sclerosis Followed by Right Temporal Variant (2026)](https://pubmed.ncbi.nlm.nih.gov/41645024/) - Ann Clin Transl Neurol

Allen Brain Atlas Resources

[Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
[Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
[Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury
[BrainSpan Atlas of the Developing Human Brain](https://brainspan.org/) - Developmental gene expression data

Disease Pathogenesis

Mermaid diagram (expand to render)

PLS Pathogenesis

Upper Motor Neuron Degeneration: Selective loss of corticospinal tract neurons

Excitotoxicity: Glutamate-mediated neuronal damage

Progression: Typically slower than ALS, remains pure upper motor neuron syndrome

Differential Diagnosis: Distinguished from ALS by absence of lower motor neuron signs

References

[Pringle CE, Hudson AJ, Munoz DG, et al, Primary lateral sclerosis (1992)](PMID: 1606479(https://pubmed.ncbi.nlm.nih.gov/1606479/))

[Tartaglia MC, Rowe A, Findlater K, et al, Differentiation between primary lateral sclerosis and amyotrophic lateral sclerosis (2007)]([DOI:10.1212/01.wnl.0000253188.46396.73](https://doi.org/10.1212/01.wnl.0000253188.46396.73))

[Iwata NK, Kwon Y, Kimura F, et al, Primary lateral sclerosis: Epidemiology (2011)](PMID: 22151968(https://pubmed.ncbi.nlm.nih.gov/22151968/))

[Singer MA, Statland JM, Wolfe GI, Barohn RJ, Primary lateral sclerosis (2007)]([DOI:10.1002/mus.20731](https://doi.org/10.1002/mus.20731))

[Zhai P, Paganoni P, Bruijn L, Primary lateral sclerosis: The search for a biomarker (2021)]([DOI:10.1016/j.jns.2021.117384](https://doi.org/10.1016/j.jns.2021.117384))

[Chio A, Calvo A, Moglia C, et al, Population-based study of survival among patients with primary lateral sclerosis (2021)]([DOI:10.1212/WNL.0000000000011740](https://doi.org/10.1212/WNL.0000000000011740))

[Konno H, Yamamoto T, Iwasaki Y, Iizuka H, Primary lateral sclerosis: Neuropathological features (1986)]([DOI:10.1007/BF00685974](https://doi.org/10.1007/BF00685974))

[Rothstein JD, Excitotoxicity and neurodegeneration in amyotrophic lateral sclerosis (1995)](PMID: 8906192(https://pubmed.ncbi.nlm.nih.gov/8906192/))

[Beal MF, Oxidatively modified proteins in aging and disease (2002)]([DOI:10.1016/S0891-5849(02](https://doi.org/10.1016/S0891-5849(02))

[Mattiazzi M, D'Aurelio M, Gajewski CD, et al, Mutated mitochondrial SOD2 and ALS (2002)]([DOI:10.1083/jcb.200207080](https://doi.org/10.1083/jcb.200207080))

[De Vos KJ, Hafezparast M, Neurobiology of axonal transport defects in motor neuron diseases: Therapeutic implications (2009)]([DOI:10.1007/s12017-009-8067-0](https://doi.org/10.1007/s12017-009-8067-0))

[McGeer PL, McGeer EG, Inflammatory processes in amyotrophic lateral sclerosis (2002)]([DOI:10.1002/mus.10192](https://doi.org/10.1002/mus.10192))

[Valdmanis PN, Dupre N, Bouchard JP, et al, Three families with primary lateral sclerosis (2007)]([DOI:10.1212/01.wnl.0000251307.68214.db](https://doi.org/10.1212/01.wnl.0000251307.68214.db))

[Siddique N, Siddique T, Genetics of primary lateral sclerosis (2009)]([DOI:10.1002/mus.21399](https://doi.org/10.1002/mus.21399))

[Durr A, Davoine CS, Paternotte C, et al, Phenotype of autosomal dominant spastic paraplegia linked to chromosome 2p (2000)]([DOI:10.1212/WNL.54.4.804](https://doi.org/10.1212/WNL.54.4.804))

[Sepulveda-Falla D, Matschke J, Lagunoff M, et al, HTRA1 mutations cause primary lateral sclerosis (2014)]([DOI:10.1002/ana.24187](https://doi.org/10.1002/ana.24187))

[Gotkine M, Argov Z, Clinical differentiation between primary lateral sclerosis and upper motor neuron predominant ALS (2007)]([DOI:10.1016/S0072-9752(07](https://doi.org/10.1016/S0072-9752(07))

[Young RR, Spasticity: A review (1994)](PMID: 7969957(https://pubmed.ncbi.nlm.nih.gov/7969957/))

[Schiffer R, Pope LE, Pseudobulbar affect in neurological disorders (2006)]([DOI:10.1038/nrneurol.2006.168](https://doi.org/10.1038/nrneurol.2006.168))

[Quinn C, Edmundson C, Wadden C, et al, Primary lateral sclerosis: A diagnostic challenge (2020)]([DOI:10.1016/j.jns.2019.116644](https://doi.org/10.1016/j.jns.2019.116644))

[Lou JS, Benatar M, Weiss MD, et al, Fatigue in primary lateral sclerosis (2009)]([DOI:10.1212/01.wnl.0000338053.45349.2f](https://doi.org/10.1212/01.wnl.0000338053.45349.2f))

[Bruijn LI, Miller TM, Cleveland DW, Unraveling the mechanisms involved in motor neuron degeneration in ALS (2004)]([DOI:10.1146/annurev.neuro.27.070203.144244](https://doi.org/10.1146/annurev.neuro.27.070203.144244))

[Pringle CE, Primary lateral sclerosis: A distinct clinical entity? Muscle Nerve (1999)](PMID: 10514243(https://pubmed.ncbi.nlm.nih.gov/10514243/))

[Stark FM, Moosa S, Mak HK, et al, Primary lateral sclerosis: A reappraisal (2021)]([DOI:10.1016/j.jns.2020.117271](https://doi.org/10.1016/j.jns.2020.117271))

[Younger DS, Lou XL, Adelman L, et al, Adult-onset motor neuron disease: Differential diagnosis (1998)]([DOI:10.1016/S0022-510X(98](https://doi.org/10.1016/S0022-510X(98))

[Francisco GE, Kesar TM, Pero S, Optimizing pharmacologic management of spasticity (2021)]([DOI:10.1016/j.pmr.2021.01.003](https://doi.org/10.1016/j.pmr.2021.01.003))

[Schiffer R, Pope LE, Review of pseudobulbar affect including a perspective on therapeutic trials (2006)]([DOI:10.3810/pgm.2008.11.1939](https://doi.org/10.3810/pgm.2008.11.1939))

[Jaiswal MK, Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs (2019)]([DOI:10.1002/med.21528](https://doi.org/10.1002/med.21528))

[Benatar M, Wuu J, Andersen PM, et al, Design of a phase 3 trial of edaravone for primary lateral sclerosis (2022)]([DOI:10.1002/acn3.51547](https://doi.org/10.1002/acn3.51547))

[Turner MR, Kiernan MC, Leigh PN, Talbot K, Biomarkers in amyotrophic lateral sclerosis (2009)]([DOI:10.1038/nrneurol.2008.141](https://doi.org/10.1038/nrneurol.2008.141))

[Wicks P, Abrahams S, Maki D, et al, Survival in primary lateral sclerosis (2007)]([DOI:10.1212/01.wnl.0000252943.97209.7d](https://doi.org/10.1212/01.wnl.0000252943.97209.7d))

[Wolpaw JR, et al, Brain-computer interfaces for communication and control (2004)]([DOI:10.1109/JPROC.2004.829006](https://doi.org/10.1109/JPROC.2004.829006))

[Pichiorri F, et al, Brain-computer interface aids for the rehabilitation of stroke patients (2015)]([DOI:10.1016/j.brs.2014.12.001](https://doi.org/10.1016/j.brs.2014.12.001))

📖 View canonical wiki page →

Related Entities

diseases-primary-lateral-sclerosis

▸Metadataorigin_type: v1_polymorphic_backfill

slug	diseases-primary-lateral-sclerosis
kg_node_id	None
entity_type	disease
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-286ee0012745
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'diseases-primary-lateral-sclerosis'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

25%

Debates

0

Incoming

5

Outgoing

7

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Primary Lateral Sclerosis (PLS)

Primary Lateral Sclerosis

Overview

Epidemiology

Pathophysiology

Upper Motor Neuron Degeneration

Primary Lateral Sclerosis

Overview

Epidemiology

Pathophysiology

Upper Motor Neuron Degeneration

Molecular Mechanisms

Genetic Factors

Clinical Presentation

Core Symptoms

Disease Progression

Distinction from ALS

Diagnosis

Clinical Criteria

Diagnostic Workup

Differential Diagnosis

Treatment and Management

Pharmacological Approaches

Symptomatic Management

Disease-Modifying Therapies

Non-Pharmacological Interventions

Rehabilitation

Assistive Devices

Nutritional Support

Emerging Therapies

Clinical Trials

Research Directions

Brain-Computer Interface Therapy

Current Applications

Emerging Technologies

Clinical Evidence

Cross-References

Prognosis

Research Directions

Current Knowledge Gaps

Active Research Areas

See Also

External Links

Recent Research (2024-2026)

Allen Brain Atlas Resources

Disease Pathogenesis

PLS Pathogenesis

References

💬 Discussion